Elafin selectively regulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis

Gynecologic Oncology

Volumn 125, Issue 3, 2012, Pages 727-733

  Wei, Huafeng ^a,b   Hellström, Karl Erik ^a   Hellström, Ingegerd ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Drug resistance; Elafin; Genotoxic drugs; Ovarian cancer

Indexed keywords

CARBOPLATIN; CASPASE 3; CISPLATIN; CYCLOPHOSPHAMIDE; ELAFIN; FLUOROURACIL; LIPOCORTIN 5; PACLITAXEL; SHORT HAIRPIN RNA;

APOPTOSIS; CANCER CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; DEPOLYMERIZATION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL OVARIAN CARCINOMA; GENE SILENCING; GENOTOXICITY; HUMAN; HUMAN CELL; MICROTUBULE; OVARY CANCER; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CISPLATIN; ELAFIN; FEMALE; FLUOROURACIL; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HUMANS; MICE; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; TRANSFECTION;

EID: 84861191429     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.03.018     Document Type: Conference Paper

References (23)

1. R.P. Perez, A.K. Godwin, T.C. Hamilton, and R.F. Ozols Ovarian cancer biology Semin Oncol 18 1991 186 204
2. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and T. Murray Cancer statistics, 2008 CA Cancer J Clin 58 2008 71 96
3. E.E. Partridge, and M.N. Barnes Epithelial ovarian cancer: prevention, diagnosis, and treatment CA Cancer J Clin 49 1999 297 320
4. S.E. Williams, T.I. Brown, A. Roghanian, and J.-M. Sallenave SLPI and elafin: one glove, many fingers Clin Sci 110 2006 21 35
5. L. Shaw, and O. Wiedow Therapeutic potential of human elafin Biochem Soc Trans 39 2011 1450 1454
6. D. Bouchard, D. Morisset, Y. Bourbonnais, and G.M. Tremblay Proteins with whey-acidic-protein motifs and cancer Lancet Oncol 7 2006 167 174
7. I. Hellström, J. Raycraft, and M. Hayden-Ledbetter The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma Cancer Res 63 2003 3695 3700
8. I. Hellstrom, and K.E. Hellstrom Two novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma Expert Opin Med Diagn 5 2011 227 240
9. H.A. Alkemade, H.O. Molhuizen, I.M. van Vlijmen-Willems, U.J. van Haelst, and J. Schalkwijk Differential expression of SKALP/elafin in human epidermal tumors Am J Pathol 143 1993 1679 1687
10. H.A. Alkemade, I.M. van Vlijmen-Willems, U.J. van Haelst, P.C. van de Kerkhof, and J. Schalkwijk Demonstration of skinderived antileukoproteinase (SKALP) and its target enzyme human leukocyte elastase in squamous cell carcinoma J Pathol 174 1994 121 129
11. P.A. Robinson, A.F. Markham, J. Schalkwijk, and A.S. High Increased elafin expression in cystic, dysplastic and neoplastic oral tissues J Oral Pathol Med 25 1996 135 139
12. S. Yamamoto, H. Egami, T. Kurizaki, H. Ohmachi, N. Hayashi, and T. Okino Immunohistochemical expression of SKALP/elafin in squamous cell carcinoma of the oesophagus Br J Cancer 76 1997 1081 1086
13. B.A. Smith, W.J. Kennedy, P. Harnden, P.J. Selby, L.K. Trejdosiewicz, and J. Southgate Identification of genes involved in human urothelial cell-matrix interactions: implications for the progression pathways of malignant urothelium Cancer Res 61 2001 1678 1685
14. U. Westin, M. Nystrom, I. Ljungcrantz, B. Eriksson, and K. Ohlsson The presence of elafin, SLPI, IL1-RA, and STNFa RI in head and neck squamous cell carcinomas and their relation to the degree of tumor differentiation Mediators Inflamm 11 2002 7 12
15. N. Yoshida, H. Egami, J. Yamashita, E. Takai, Y. Tamori, and N. Fujino Immunohistochemical expression of SKALP/elafin in squamous cell carcinoma of human lung Oncol Rep 9 2002 495 501
16. A. Saidi, S. Javerzat, A. Bellahcene, J. de Vos, L. Bello, and V. Castronovo Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma Int J Cancer 122 2008 2187 2198
17. A. Clauss, V. Ng, J. Liu, H. Piao, M. Russo, and N. Vena Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival Neoplasia 12 2010 161 172
18. M. Schummer, W.V. Ng, R.E. Bumgarner, P.S. Nelson, B. Schummer, and D.W. Bednarski Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas Gene 238 1999 375 385
19. I. Hellstrom, J.A. Ledbetter, and N. Scholler CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer Proc Natl Acad Sci U S A 98 2001 6783 6788
20. S. Fulda, and K.M. Debatin Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy Oncogene 25 2006 4798 4811
21. J.A. Caruso, K.K. Hunt, and K. Keyomarsi The neutrophil elastase inhibitor elafin triggers rb-mediated growth arrest and caspase-dependent apoptosis in breast cancer Cancer Res 70 2010 7125 7136
22. K.S. Yu, Y. Lee, C.M. Kim, E.C. Park, J. Choi, and D.S. Lim The protease inhibitor, elafin, induces p53-dependent apoptosis in human melanoma cells Int J Cancer 127 2010 1308 1320
23. G. Aung, F. Niyonsaba, H. Ushio, S. Ikeda, K. Okumura, and H. Ogawa Elafin and secretory leukocyte protease inhibitor stimulate the production of cytokines and chemokines by human keratinocytes via MAPK/ERK and NF-κB activation J Dermatol Sci 63 2011 128 131